Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Non-Current Assets (2017 - 2025)

Historic Non-Current Assets for Arcus Biosciences (RCUS) over the last 9 years, with Q3 2025 value amounting to $117.0 million.

  • Arcus Biosciences' Non-Current Assets fell 3236.99% to $117.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $505.0 million, marking a year-over-year decrease of 4065.8%. This contributed to the annual value of $134.0 million for FY2024, which is 4924.24% down from last year.
  • Arcus Biosciences' Non-Current Assets amounted to $117.0 million in Q3 2025, which was down 3236.99% from $129.0 million recorded in Q2 2025.
  • Arcus Biosciences' 5-year Non-Current Assets high stood at $330.0 million for Q4 2021, and its period low was $93.2 million during Q1 2021.
  • Moreover, its 5-year median value for Non-Current Assets was $234.0 million (2023), whereas its average is $213.8 million.
  • As far as peak fluctuations go, Arcus Biosciences' Non-Current Assets soared by 201878.06% in 2021, and later plummeted by 4924.24% in 2024.
  • Over the past 5 years, Arcus Biosciences' Non-Current Assets (Quarter) stood at $330.0 million in 2021, then decreased by 29.39% to $233.0 million in 2022, then grew by 13.3% to $264.0 million in 2023, then plummeted by 49.24% to $134.0 million in 2024, then decreased by 12.69% to $117.0 million in 2025.
  • Its Non-Current Assets was $117.0 million in Q3 2025, compared to $129.0 million in Q2 2025 and $125.0 million in Q1 2025.